The Prostate Health Education Network: Prostate Health Education and Awareness

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Number: NCT02465060 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers Number: NCT02484404 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Number: NCT02713269 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy Number: NCT02946996 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina Sponsor Trial Information Trial Location(s) and Contact(s)
Apalutamide With or Without Abiraterone, Hormone, and Prednisone in Treating High-Risk Patients Undergoing Surgery Number: NCT02949284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Number: NCT02960022 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Astellas Pharma Global Development, Inc.\|Pfizer\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of Androgen Treatment in High-Risk Biochemically Relapsed Prostate Cancer Number: NCT03009981 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: 3 Sponsor(s): Alliance Foundation Trials, LLC.\|Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s)	Clinical Study of change in brain structure or activity in men treated with androgen receptor therapies such as abiraterone acetate and enzalutamide Number: NCT03016741 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s)
Study of Olaparib in Men With High-Risk Recurrent Prostate Cancer Following Prostate Surgery Number: NCT03047135 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s)	Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Number: NCT03150810 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): BeiGene\|Myriad Genetics, Inc. Sponsor Trial Information Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Number: NCT03170960 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s)	18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer Number: NCT03181867 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Number: NCT03333616 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s)	Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel Number: NCT03419234 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s)
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma Number: NCT03436654 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s)	Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer Number: NCT03439033 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s)
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery Number: NCT03541850 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery Number: NCT03541928 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The Methodist Hospital System Sponsor Trial Information Trial Location(s) and Contact(s)
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations Number: NCT03570619 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Michigan Cancer Center\|Memorial Sloan Kettering Cancer Center\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s)	Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer Number: NCT03581500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of Nivolumab in Patients With High-Risk Recurrent Prostate Cancer Number: NCT03637543 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Beth Israel Deaconess Medical Center\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s)	Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Number: NCT03678025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Southwest Oncology Group\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone Number: NCT03707184 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah Sponsor Trial Information Trial Location(s) and Contact(s)	A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) Number: NCT03748641 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of Pembrolizumab Plus Androgen Receptor Targeting Prior to Prostatectomy for High Risk Patients Number: NCT03753243 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Merck Sharp & Dohme Corp.\|Astellas Pharma Inc\|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s)	A Study of Apalutamide in Participants With High Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Number: NCT03767244 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s)
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT Number: NCT03777982 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Dana-Farber Cancer Institute\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s)	(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes Number: NCT03796195 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s)
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Number: NCT03821792 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer Number: NCT03824275 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\| Phase 3 Sponsor(s): Columbia University Sponsor Trial Information Trial Location(s) and Contact(s)
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer Number: NCT03833921 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Martha Mims\|Baylor College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s)	Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer Number: NCT03860987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Number: NCT03899987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Roswell Park Cancer Institute\|National Cancer Institute (NCI)\|Hemispherx Biopharma Sponsor Trial Information Trial Location(s) and Contact(s)	A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer Number: NCT03910660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): BioXcel Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s)
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer Number: NCT03964337 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Duke University\|Exelixis Sponsor Trial Information Trial Location(s) and Contact(s)	Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer Number: NCT03976843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s)
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer Number: NCT03987386 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Number: NCT03999515 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington\|National Cancer Institute (NCI)\|Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s)
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Number: NCT04019327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s)	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Number: NCT04030559 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, Davis\|National Cancer Institute (NCI)\|Janssen, LP Sponsor Trial Information Trial Location(s) and Contact(s)
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers Number: NCT04037358 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s)	Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors Number: NCT04126070 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xiao X. Wei\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s)
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer Number: NCT04134208 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer Number: NCT04134260 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate Number: NCT04136353 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): University of Sydney\|Australian and New Zealand Urogenital and Prostate Cancer Trials Group\|Bayer\|Cancer Trials Ireland\|Canadian Cancer Trials Group\|Memorial Sloan Kettering Cancer Center\|Prostate Cancer Clinical Trials Consortium Sponsor Trial Information Trial Location(s) and Contact(s)	Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) Number: NCT04157088 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s)
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer Number: NCT04167969 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Elucida Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes Number: NCT04171700 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Clovis Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s)
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer Number: NCT04179968 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana Mathews\|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s)	A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer Number: NCT04194554 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s)
Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Number: NCT04246671 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Bavarian Nordic Sponsor Trial Information Trial Location(s) and Contact(s)	Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer Number: NCT04253483 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer Number: NCT04262154 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Genentech, Inc. Sponsor Trial Information Trial Location(s) and Contact(s)	Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer Number: NCT04267887 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): OHSU Knight Cancer Institute\|National Cancer Institute (NCI)\|Oregon Health and Science University Sponsor Trial Information Trial Location(s) and Contact(s)
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Number: NCT04383210 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Elevation Oncology Sponsor Trial Information Trial Location(s) and Contact(s)	18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer Number: NCT04390880 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Greater Los Angeles Healthcare System Sponsor Trial Information Trial Location(s) and Contact(s)
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer Number: NCT04402151 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Number: NCT04423029 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Dragonfly Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s)
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Subjects With Malignant Solid Tumors Number: NCT04424641 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Genmab Sponsor Trial Information Trial Location(s) and Contact(s)	Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer Number: NCT04457245 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Jonsson Comprehensive Cancer Center\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s)
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency Number: NCT04493853 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s)	A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases Number: NCT04523207 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s)
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Number: NCT04550494 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s)
68 Ga-PSMA for High Risk Prostate Cancer Number: NCT04614363 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): The Methodist Hospital System Sponsor Trial Information Trial Location(s) and Contact(s)	PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer Number: NCT04700332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Hoag Memorial Hospital Presbyterian Sponsor Trial Information Trial Location(s) and Contact(s)
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer Number: NCT04725903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Emory University Sponsor Trial Information Trial Location(s) and Contact(s)	18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer Number: NCT04727736 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ashok Muthukrishnan\|Progenics Pharmaceuticals, Inc.\|University of Pittsburgh Sponsor Trial Information Trial Location(s) and Contact(s)

Total: 68 Clinical Trials

PHEN,Inc. © 2021 All rights reserved